Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Burton Eisenberg, Margaret von Mehren, Jonathan Harris et al.|Journal of Surgical Oncology|2008Cited by 419
A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic CarcinomaMark S. Talamonti, Cornelius J. McGinn, William Small et al.|Annals of Surgical Oncology|2006Cited by 237
The Metastatic/Examined Lymph Node Ratio is an Important Prognostic Factor after Pancreaticoduodenectomy for Pancreatic AdenocarcinomaAdam C. Berger, John P. Hoffman, James C. Watson et al.|The American Surgeon|2004Cited by 214
Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132Dian Wang, Burton Eisenberg, John M. Kane et al.|Annals of Surgical Oncology|2011Cited by 202
Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal CancerSteven J. Cohen, Neal J. Meropol, R. Katherine Alpaugh et al.|Clinical Colorectal Cancer|2006Cited by 189